ProQR Therapeutics
"ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines."
The firm is focused on the creation of: "transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome type 2 and dystrophic epidermolysis bullosa."
The company states: "Based on aunique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind."
Latest ProQR Therapeutics News & Features
27 September 2023
2 August 2023
11 August 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze